Black Diamond Therapeutics (NASDAQ:BDTX) Raised to "Outperform" at Wedbush
Wedbush upgraded shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) from a neutral rating to an outperform rating in a research note published on Tuesday, Marketbeat Ratings reports. Wedbush currently has $10.00 price objective on the stock. Wedbush also issued estimates for Black Diamond Therapeutics’ FY2026 earnings at ($0.64) EPS and FY2027 earnings at […]